Benefits
Studied in children with repeated sore throat (K12)
The one systematic review cited on this page (Wilcox 2019, Clinical Microbiology and Infection) found only four trials of K12 for sore throat, covering 1,846 people, and judged all four to be of poor quality using the standard Cochrane risk of bias assessment. Two trials in children had mixed results, and one trial reported fewer flare-ups of chronic adenoid inflammation. The single placebo controlled trial in adults with acute sore throat found no significant benefit. The reviewers concluded that further trials are needed before K12 can be considered a preventive. A separate open-label study in children with a history of repeated sore throat, described further down this page, reported far fewer episodes over the following year, but it had no placebo group and everyone involved knew who was taking the lozenge.
Breath odour, studied in small short trials
K12 is thought to compete with the mouth bacteria that make the sulfur compounds behind bad breath. The research here is small and short: the study on this page ran one week per arm in 23 adults and used three lozenges a day, not the single 1 billion CFU lozenge listed above. The only systematic review cited on this page looked at sore throat, not breath, so there is no high quality review evidence behind the breath claims, and how long any effect lasts after stopping is not established.
Mouth bacteria linked to tooth decay (M18, studied in children)
M18 is a different strain from K12, and evidence for one does not carry over to the other. In laboratory work M18 produces salivaricins that act against Streptococcus mutans, a bacterium linked to tooth decay. The study described further down this page was run in 100 children already considered at high risk of cavities, so it describes what was measured in those children rather than what a lozenge does for a healthy mouth. The systematic review cited on this page covered K12 and sore throat only and did not look at M18 or at teeth. Lozenges are not a substitute for brushing, flossing or dental care.
Looked at in children prone to repeated ear infections (K12)
K12 has been looked at in children who get repeated middle ear infections, on the proposed idea that it settles at the back of the nose and throat and competes with bacteria that can travel to the middle ear. That is a proposed mechanism rather than a proven one, and the single systematic review cited on this page covered sore throat only and did not assess ear infections. Ear infections in children are a medical problem for a doctor to manage, not something to self treat with a lozenge.
Mechanism of action
Salivaricin production — bacteriocin-like inhibitory substances (BLIS)
S. salivarius K12 produces salivaricins A2 and B that inhibit Group A Streptococcus, Streptococcus pneumoniae, and other oropharyngeal pathogens. M18 strain produces salivaricin M, A2, B, and 9 — most active against S. mutans. In laboratory testing these bacteriocins act mainly on closely related Streptococcus species. Whether they leave the rest of the normal mouth flora untouched during everyday use has not been clearly shown.
Niche occupation in oral cavity and throat
Both K12 and M18 colonize tongue, gum line, and oropharynx after lozenge dissolution. The idea is that holding onto these spots leaves less room and fewer nutrients for unwanted bacteria. This competitive exclusion model comes from laboratory and colonization work rather than from evidence of fewer infections in people. Colonization is transient (weeks) so daily dosing is needed for ongoing protection.
VSC-producing bacteria displacement
Halitosis is primarily caused by anaerobic bacteria (Solobacterium moorei, Atopobium, Fusobacterium) producing volatile sulfur compounds (hydrogen sulfide, methyl mercaptan). K12 is proposed to compete with these species and to act on them through its salivaricins, based mainly on laboratory work.
Adhesion to oral epithelium
S. salivarius expresses surface adhesins (similar in structure to S. mutans adhesins) that bind oral epithelial receptors and salivary glycoproteins. Strong adhesion enables niche persistence beyond simple lozenge transit.
Clinical trials
Open-label controlled trial. Children with history of recurrent strep pharyngitis received K12 lozenge (1 billion CFU/day) for 90 days; control group received standard care. Both groups followed for next year of strep episodes.
65 children (39 K12, 26 control), age 3–13.
As reported: 0.4 strep throat episodes per year in the K12 group versus 4.0 in the control group, with fewer antibiotic prescriptions, tonsillitis episodes and ear infections. K12 was well tolerated with no adverse events. Read the size of these numbers cautiously: there was no placebo, families and staff knew who was taking the lozenge, the groups were small and unequal (39 versus 26 children), and the systematic review cited on this page judged the K12 sore throat trials it examined to be of poor quality.
Crossover, randomized, double-blind, placebo-controlled trial. Subjects with halitosis received K12 lozenges or placebo lozenges, 3 lozenges/day for 1 week each, with washout.
23 adults with diagnosed halitosis (organoleptic score ≥2).
Sulfur compound readings and judged breath odour scores improved with K12 compared with placebo. This was a very small study, 23 adults for one week per arm, using three lozenges a day rather than the one lozenge dose listed at the top of this page, so it shows a short term signal rather than a settled result. How long any effect lasts after people stop taking it was not reliably established in a group this size.
12-month, randomized, double-blind, placebo-controlled trial. Children with high caries risk received M18 lozenge (1 billion CFU/day) or placebo.
100 children with high caries risk.
As reported, the M18 group had lower counts of Streptococcus mutans at 6 months and less plaque and fewer new cavities at 12 months. This was run in children already at high risk of cavities, so it describes what happened in that group rather than what a lozenge does for a healthy mouth. It also tested M18, so it says nothing about the K12 strain used in throat and breath products.